

FOR IMMEDIATE RELEASE

Contact: Jody McNannay, Co-Founder, Curadite
(503) 310-5063
jmcnannay@curadite.com

CURADITE, INC. TARGETS OPIOID DIVERSION REDUCTION WITH GRANT FROM BUSINESS OREGON

Beaverton, OR (February 27, 2019) – [Curadite, Inc.](#) has received a \$98,000 grant from Business Oregon for a pilot program designed to prevent opioid addiction by preventing controlled substance diversion. Working with a regional pharmacy partner, Curadite will demonstrate next generation technology that is capable of monitoring, recording and reporting chain-of-custody for controlled substances in Skilled Nursing and Assisted Living Facilities (SNF/ALF).

The Business Oregon award is part of the Oregon Innovation Council's highly competitive Enhanced Phase 0 program, which supports the creation and growth of Oregon companies with high-growth potential emerging from science and research.

Curadite's three-phase pilot is designed to equip healthcare providers and pharmacists with tangible evidence that controlled substance medications are being administered as prescribed and are not being diverted. Despite the efforts of healthcare and public safety leaders to address issues of opioid addiction and illegal access and use, studies show that 10-15 percent of healthcare workers participate in some form of controlled substance abuse at some point in their careers. Both the Centers for Disease Prevention and Control (CDC) and the Centers for Medicare and Medicaid Services (CMS) have expressed specific concern regarding opioid diversion in SNFs.

"In addition to supporting one of Oregon's most fragile populations (the elderly)," explains Curadite CEO Dennis McNannay, "this work will support new medication adherence technologies can help the healthcare community gain the greatest benefit from all prescription medications, while protecting society from the destructive impact of opioid addiction."

The growing demand for in-home care (e.g. hospice/palliative) provides increased opportunities for diversion; by maintaining chain of custody records for controlled substances. Curadite's Medication Management Platform ensures that patients dealing with chronic pain or receiving palliative or hospice services have access to appropriate pain medication, while simultaneously addressing the public health concerns surrounding diversion.

By incorporating the latest intelligent packaging and replacing manual recordkeeping with cloud-based, digital records, Curadite's also provides safeguards for the nurses and med techs responsible for medication administration. The Mayo Clinic, for example, noted that healthcare staff members, who are unaware of their colleague's impairment, "may share patient-care responsibilities that could result in adverse patient outcomes, placing all members of the care team at risk for medicolegal liability." By establishing digital chain-of-custody throughout the controlled substance lifecycle, Curadite supports the safe, effective utilization of controlled substances.

Business Oregon awards Enhanced Phase 0 grants through a competitive application and review process.

###

About Curadite

Curadite empowers patients, clinicians, caregivers and family members to work together to improve medication adherence with the support of our intelligently linked, proactive medication management platform. With Curadite's MMP, healthcare providers have tangible evidence that medication is being administered to patients as prescribed and is not being diverted. With the addition of data analytics, visualization and alerts, our cloud-based dashboard and reporting system supports the safe, effective use of controlled substances.

For more information, visit www.curadite.com

About Business Oregon

Business Oregon invests in Oregon businesses, communities, and people to promote a globally competitive, diverse, and inclusive economy.

For more information, visit <https://www.oregon4biz.com/About-Us/>